文献速递前列腺癌

门诊局部麻醉下经会阴前列腺穿刺活检的初步经验:PrecisionPoint系统

Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System.
PubMed 文献 · Urology · 2018-02-01

该研究回顾性分析了43例在门诊使用PrecisionPoint经会阴穿刺系统、局部麻醉下接受前列腺活检的男性患者,中位PSA为6.1 ng/mL。总体前列腺癌检出率为48.8%,无感染性并发症发生,尽管所有病例均未使用围手术期抗生素。

要点

  • 门诊局部麻醉下经会阴穿刺活检可行,无需围手术期抗生素。
  • 总体癌检出率48.8%,主动监测组为66.7%,筛查组为41.9%。
  • 术后并发症3例(7.0%),包括尿潴留2例和需导尿的肉眼血尿1例,无感染。

核心结论

  • PrecisionPoint系统可在局部麻醉下成功完成门诊经会阴前列腺活检,无需围手术期抗生素,癌检出率可接受且无感染性并发症。

研究设计与样本

  • 回顾性病例系列,经机构审查委员会批准,纳入2017年1月4日至2017年8月23日期间43例在门诊接受经会阴前列腺活检的男性。

主要发现

  • 43例患者中位血清PSA为6.1 ng/mL(范围0.8-32.9)。
  • 12例(27.9%)活检用于低危前列腺癌主动监测,31例(72.1%)用于癌症筛查。
  • 总体21例(48.8%)检出前列腺癌;主动监测组8/12(66.7%)检出癌,其中2/12(16.7%)为Gleason≥3+4=7;筛查组13/31(41.9%)检出癌,其中5例(16.1%)为Gleason≥3+4=7。
  • 3例(7.0%)出现术后并发症:2例(4.7%)尿潴留,1例(2.3%)肉眼血尿需导尿;无感染性并发症,所有病例均未使用围手术期抗生素。

临床怎么用

  • 在门诊局部麻醉下使用PrecisionPoint系统行经会阴前列腺活检,可不常规使用围手术期抗生素,但需注意术后尿潴留和血尿风险。

局限性

  • 回顾性设计、样本量小(43例)、单中心、缺乏对照组,随访时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe our procedural technique and initial outcomes performing in-office transperineal prostate biopsies using the PrecisionPoint Transperineal Access System (Perineologic, Cumberland, MD). PATIENTS AND METHODS: Following institutional review board approval, we retrospectively reviewed the records of men who underwent an in-office transperineal prostate biopsy using the PrecisionPoint device. Records were reviewed for baseline characteristics, biopsy results, and postbiopsy complications. RESULTS: Between January 4, 2017 and August 23, 2017, 43 men underwent an in-office transperineal prostate biopsy using the PrecisionPoint Transperineal Access System. Patients had a median serum prostate specific antigen level of 6.1 ng/mL (range 0.8-32.9). Of the 43 biopsies, 12 (27.9%) were performed for active surveillance of low-risk prostate cancer and 31 (72.1%) were performed for cancer screening. Overall, 21 (48.8%) men were found to have prostate cancer. Among those on active surveillance, cancer was detected in 8 of 12 (66.7%) patients, with 2 of 12 (16.7%) found to have Gleason ≥3 + 4 = 7 prostate cancer. Additionally, cancer was detected in 13 of 31 (41.9%) patients undergoing a biopsy for prostate cancer screening, with 5 (16.1%) found to have Gleason ≥3 + 4 = 7 disease. In total, 3 (7.0%) patients experienced a postbiopsy complication: 2 (4.7%) with urinary retention and 1 (2.3%) with gross hematuria requiring catheterization. No patient experienced an infectious complication despite omission of periprocedural antibiotics in all cases. CONCLUSION: The PrecisionPoint device allowed for the successful performance of in-office transperineal prostate biopsies under local anesthesia without the need for periprocedural antibiotics. We observed an acceptable cancer detection rate with no infectious complications.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Meyer AR, Joice GA, Schwen ZR, et al. Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. Urology. 2018. PMID: 29409845. doi:10.1016/j.urology.2018.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。